Navigation Links
Researchers from the University of Navarra analyze new kinds of cancer-fighting antibodies

Two researchers from the University Hospital and the Center for Applied Medical Research (CIMA) from the University of Navarra have published an article in Nature Cancer Reviews, one of the leading scientific journals in the area of cancer studies. The article, written by Ignacio Melero and Sandra Hervas-Stubbs, together with other scientists from the United States and Great Britain, addresses the use of a new pharmaceutical family with practical applications in cancer and chronic viral illnesses.

Specifically, the article discusses using monoclonal antibodies in order to stimulate the immune system. In this therapy the antibodies are directed to the immune system cells in order to provoke a stronger reaction against cancer. This has the advantage of exploiting a mechanism with an action distinct from the other strategies currently being used to treat cancer, and is capable of interacting with the current treatments so as to make both forms of treatment more powerful.

Currently this treatment is being tested in patients with melanoma, kidney and ovarian cancer because there are more ways of measuring the response of the immune system, but he expects to be able to expand this to include other forms of cancer.

Five cancer-fighting agents being tested

The first cancer-fighting agent of this kind, anti-CTLA-4, began to be tested in patients in 1999. In melanoma treatment, between 15 and 20% of clinical objectives have been reached (reduction or disappearance of the tumor), which the researchers see as a positive sign to continue with the research.

Currently, the researchers study its benefits in cancer survivors through two clinical tests in the third phase. In two years we will test its use as the sole means of treatment, and we will need more time in order to know if its effects in treatment combinations are as positive as the results on test animals predict.

Aside from this, there are another f our members of this monoclonal antibiotic family, which stimulate the immune system, currently being developed. Their use in patients began a year and a half ago, and to date no conclusions as to their effectiveness has been published.


Source:Elhuyar Fundazioa

Related biology news :

1. Researchers discover way to make cells in the eye sensitive to light
2. Researchers find how protein allows insects to detect and respond to pheromones
3. Researchers Uncover Key Step In Manufacture of Memory Protein
4. Researchers reveal the infectious impact of salmon farms on wild salmon
5. Researchers identify target for cancer drugs
6. Researchers discover molecule that causes secondary stroke
7. Researchers find missing genes of ancient organism
8. Researchers trace evolution to relatively simple genetic changes
9. Researchers add new tool to tumor-treatment arsenal
10. UF Researchers Map Bacterial Proteins That Cause Tooth Loss
11. VCU Researchers Identify Networks Of Genes Responding To Alcohol In The Brain
Post Your Comments:

(Date:9/30/2015)... 30, 2015  The global glucose monitoring device and diabetes ... says a new report on the industry from Kalorama Information. Sales ... the market, followed by continuous glucose monitoring and sensor segment, ... market for these products in its latest report, The ... , ...
(Date:9/28/2015)... NEW YORK , Sept. 28, 2015 ... platform, announced today that its expedited traveler ...  CLEAR,s innovative platform transforms travel, bringing a ... for its members. "CLEAR offers ... which enhances customer service," said Jim ...
(Date:9/28/2015)... , September 28, 2015 ... Component (Hardware & Software), Product (Scanner & Others), Application ... & Defense, & Others) & Geography Global - Forecast ... expected to reach USD 3627.90 Million by 2020, at ... Browse 65 market data T ables ...
Breaking Biology News(10 mins):
(Date:10/13/2015)... -- Amgen (NASDAQ: AMGN ) and LabCentral announced today ... 2015 selection for Golden Ticket winners, which supply each ... innovative, shared laboratory space designed as a launchpad for ... Mass. Novopyxis and Cocoon Biotech are each ... --> Cambridge, Mass. Novopyxis ...
(Date:10/13/2015)... 2015 Research and Markets( ) has ... Markets for Bone Morphogenetic Protein Growth Factor Therapy - ... --> --> Bone morphogenetic ... of bone after a fracture. In nature, these proteins ... formation of the skeleton. There are twenty different BMPs ...
(Date:10/13/2015)... and SAN DIEGO , ... Mast Therapeutics, Inc. have agreed to collaborate in the ... poloxamer 188 NF, marketed by BASF under the Kolliphor ... a variety of pharmaceutical and biological applications, such as ... is the starting material for Mast,s lead product candidate. ...
(Date:10/13/2015)... ... October 13, 2015 , ... Exotic Automation & ... solutions and components, is opening its latest Parker Store retail location in Ann, ... Exotic’s second major expansion in Metropolitan Detroit in less than a year. The ...
Breaking Biology Technology: